Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ462,5463,53,47
KB0,00
PKN53,153,2-0,49
Msft5,62
Nokia4,1514,31954,96
IBM1,11
Daimler AG39,02539,0354,44
PFE-0,34
04.08.2020 1:38:57
Indexy online
AD Index online
select
AD Index online
 

  • 03.08.2020
Transgene SA (TRNG.PA, Paris)
Závěr k 3.8.2020 Změna (%) Změna (EUR) Objem obchodů (EUR)
1,47 0,27 0,00 36 725
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 04.08.2020
Popis společnosti
Obecné informace
Název společnostiTransgene SA
TickerTNG
Kmenové akcie:Ordinary Shares
RICTRNG.PA
ISINFR0005175080
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.03.2020
Počet zaměstnanců k 31.12.2019 159
Akcie v oběhu k 31.12.2019 83 265 464
MěnaEUR
Kontaktní informace
Ulice400 Boulevard Gonthier d'Andernach
MěstoILLKIRCH-GRAFFENSTADEN
PSČ67405
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 388 279 100
Fax33388279111

Business Summary: Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Transgene SA revenues increased 88% to EUR13.3M. Net loss totaled EUR18.8M vs. income of EUR8M. Revenues reflect Bio-Production & Cooperations segment increase from EUR1.3M to EUR6.6M, Research & Development Tax Credit segment increase of 14% to EUR6.6M. Net loss reflects Other Products decrease of 99% to EUR437K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 04.08.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive Officer, Member of the Management CommitteePhilippe Archinard6017.06.201006.12.2004
Vice President - Responsible Pharmacist, Quality and Deputy CEO, Member of the Management CommitteeChristophe Ancel5401.01.2014
Vice President - Finance, Member of the Management CommitteeJean-Philippe Del3801.01.2014
Executive Vice President, Director of Research & Development, Member of the Management CommitteeEric Quemeneur5401.01.2014
Vice President Strategic Alliance, Project Management and Marketing, Member of the Management CommitteeThibaut du Fayet5001.01.2008
Member of the Management Committee, Vice President - Clinical Development, Clinical Operations and Regulatory AffairsMaud Brandely6401.01.2016
Vice President - Medical Affairs and International Development, Member of the Management CommitteeHemanshu Shah57
General Counsel, Member of the Management Committee, Corporate SecretaryJohn Felitti4801.01.2016